Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2025)

Summit Therapeutics' Other Non-Current Liabilities history spans 7 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 6.64% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, up 6.64%, while the annual FY2024 figure was $1.6 million, 4.35% up from the prior year.
  • Other Non-Current Liabilities reached $1.8 million in Q3 2025 per SMMT's latest filing, roughly flat from $1.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.3 million in Q1 2024 to a low of $1.4 million in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $2.1 million, with a median of $1.8 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 48.52% in 2022, then skyrocketed 123.5% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.8 million in 2021, then plummeted by 48.52% to $1.4 million in 2022, then grew by 9.31% to $1.6 million in 2023, then increased by 4.35% to $1.6 million in 2024, then grew by 12.27% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Other Non-Current Liabilities are $1.8 million (Q3 2025), $1.8 million (Q2 2025), and $1.7 million (Q1 2025).